Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5766)	12/15/1998 11:26:00 AM
From: tommysdad	Read Replies (1) \| Respond to of 6136

I'm not sure I should be excited about this. What am I missing? A person gets a cold. They try all the OTC elixirs for a few days. They still have a cold. They call their doctor. Two or three days later (when the cold has just about run its course), they get an appointment, and are (maybe) prescribed a few days worth of "AG7088" ("Coldzaway", let's call it). Lots of doctors might even say "take some Sudafed and come back in three days". Think of the safety profile a prescription cold medication would have to have to get approval (as safe as cough syrup?). Several major pharmaceutical companies had programs targetting the common cold, and abandoned them due to concerns like these. Does AGPH have a shot? Anyone care to comment?